Jessica Hope Roark

Array ( [id] => 10522730 [patent_doc_number] => 09249228 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-02 [patent_title] => 'Anti-Axl antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/127415 [patent_app_country] => US [patent_app_date] => 2012-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 15747 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14127415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8617227 [patent_doc_number] => 20130022539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-24 [patent_title] => 'OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/523393 [patent_app_country] => US [patent_app_date] => 2012-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 50634 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13523393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8504910 [patent_doc_number] => 20120304319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-29 [patent_title] => 'TOX3 AS A BIOMARKER FOR BREAST CANCER' [patent_app_type] => utility [patent_app_number] => 13/488058 [patent_app_country] => US [patent_app_date] => 2012-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11187 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13488058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9777394 [patent_doc_number] => 08852594 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-07 [patent_title] => 'Compositions and methods for the therapy and diagnosis of cytomegalovirus infections' [patent_app_type] => utility [patent_app_number] => 13/486569 [patent_app_country] => US [patent_app_date] => 2012-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 19 [patent_no_of_words] => 35677 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13486569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8509174 [patent_doc_number] => 20120308582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-06 [patent_title] => 'MOLECULES AND METHODS FOR MODULATING TMEM16A ACTIVITIES' [patent_app_type] => utility [patent_app_number] => 13/485311 [patent_app_country] => US [patent_app_date] => 2012-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 27641 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13485311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10876495 [patent_doc_number] => 08901283 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-02 [patent_title] => 'Anti-NKG2A antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/477888 [patent_app_country] => US [patent_app_date] => 2012-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 20 [patent_no_of_words] => 33121 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13477888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9602625 [patent_doc_number] => 20140199307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS' [patent_app_type] => utility [patent_app_number] => 14/113755 [patent_app_country] => US [patent_app_date] => 2012-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19592 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14113755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8896888 [patent_doc_number] => 08476409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-02 [patent_title] => 'Bispecific anti-IGF-1R and anti-ErbB3 antibodies' [patent_app_type] => utility [patent_app_number] => 13/451135 [patent_app_country] => US [patent_app_date] => 2012-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 139 [patent_figures_cnt] => 190 [patent_no_of_words] => 76892 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13451135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8696939 [patent_doc_number] => 20130058948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'Antibodies Directed To Gpnmb And Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/445730 [patent_app_country] => US [patent_app_date] => 2012-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 29056 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13445730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8416662 [patent_doc_number] => 20120244163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-27 [patent_title] => 'BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/443660 [patent_app_country] => US [patent_app_date] => 2012-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 27552 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13443660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9009170 [patent_doc_number] => 08524466 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-03 [patent_title] => 'Microvesicle membrane protein and application thereof' [patent_app_type] => utility [patent_app_number] => 13/443462 [patent_app_country] => US [patent_app_date] => 2012-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15176 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13443462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8464658 [patent_doc_number] => 20120269827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer' [patent_app_type] => utility [patent_app_number] => 13/434419 [patent_app_country] => US [patent_app_date] => 2012-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15267 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13434419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476697 [patent_doc_number] => 20120276104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'MULTISPECIFIC MODULAR ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/434765 [patent_app_country] => US [patent_app_date] => 2012-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 22215 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13434765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8429666 [patent_doc_number] => 20120251541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-04 [patent_title] => 'Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation' [patent_app_type] => utility [patent_app_number] => 13/433033 [patent_app_country] => US [patent_app_date] => 2012-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 26791 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13433033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10155775 [patent_doc_number] => 09187534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-17 [patent_title] => 'Multi-epitopic vaccine' [patent_app_type] => utility [patent_app_number] => 13/415877 [patent_app_country] => US [patent_app_date] => 2012-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 9 [patent_no_of_words] => 14084 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13415877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10096969 [patent_doc_number] => 09133270 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-15 [patent_title] => 'Antibody-like proteins for therapeutic and diagnostic use' [patent_app_type] => utility [patent_app_number] => 14/003989 [patent_app_country] => US [patent_app_date] => 2012-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 11355 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14003989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9286411 [patent_doc_number] => 08642742 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-02-04 [patent_title] => 'Anti-CEA antibodies' [patent_app_type] => utility [patent_app_number] => 13/408171 [patent_app_country] => US [patent_app_date] => 2012-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 33383 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13408171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10096971 [patent_doc_number] => 09133272 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-15 [patent_title] => 'Bispecific binding agents' [patent_app_type] => utility [patent_app_number] => 13/409019 [patent_app_country] => US [patent_app_date] => 2012-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 40815 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13409019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11183702 [patent_doc_number] => 09415088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-16 [patent_title] => 'Use of AGR3 for treating cancer' [patent_app_type] => utility [patent_app_number] => 14/000182 [patent_app_country] => US [patent_app_date] => 2012-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 23 [patent_no_of_words] => 15897 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14000182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405448 [patent_doc_number] => 20120237507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'Monovalent Antigen Binding Proteins' [patent_app_type] => utility [patent_app_number] => 13/406503 [patent_app_country] => US [patent_app_date] => 2012-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 18203 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13406503 [rel_patent_id] =>[rel_patent_doc_number] =>)